Core Viewpoint - CytoMed Therapeutics Limited has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre to conduct a first-in-human Phase I clinical trial for its allogeneic unmodified Gamma Delta T cells, targeting no-option cancer patients in Malaysia [1][5] Group 1: Clinical Trials and Collaborations - The new trial will complement CytoMed's ongoing Phase I CAR T clinical trial at National University Hospital Singapore, which utilizes engineered γδ T cells to target various cancers [2] - CytoMed's Chairman highlighted that the collaboration aims to provide affordable immunotherapy options for patients with limited alternatives, leveraging the innate ability of γδ T cells to detect and kill cancer cells [3] - The company has previously collaborated with MD Anderson Cancer Center, resulting in a publication that supports the potential of its CTM-GDT for treating acute myeloid leukemia [3][4] Group 2: Technology and Innovation - CytoMed focuses on developing allogeneic immunotherapies using γδ T cells derived from healthy donors, which are more cost-effective and logistically simpler compared to autologous therapies [3] - The company was established in 2018, spun off from Singapore's Agency for Science, Technology and Research, and aims to create novel cell-based therapies inspired by the success of existing CAR-T therapies [6]